Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4744840 | 1.00 | TAAR1 (0.34) | TAAR1EPHX2GAABTKMAPK1 | |
| SCHEMBL5120488 | 1.00 | TAAR1 (0.34) | TAAR1EPHX2GAABTKMAPK1 | |
| SCHEMBL5667133 | 0.97 | TAAR1 (0.36) | TAAR1EPHX2GAABTKMAPK1 | |
| SCHEMBL9937310 | 0.95 | DPP4 (0.33) | TAAR1EPHX2BTKALDH1A1LMNA | |
| SCHEMBL2679564 | 0.90 | TP53 (0.32) | — | |
| SCHEMBL1998545 | 0.90 | TP53 (0.32) | — | |
| SCHEMBL344785 | 0.90 | TP53 (0.32) | — | |
| SCHEMBL5991039 | 0.89 | HRH3 (0.33) | GAAMAPK1 | |
| SCHEMBL18825094 | 0.87 | HRH3 (0.34) | GAAMAPK1ALDH1A1HCRTR2TSHR | |
| SCHEMBL20595095 | 0.87 | CYP4A11 (0.39) | GAAMAPK1ALDH1A1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782996-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-02-15 | — | — | US | disclosed |
| EP-4288426-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | Black Diamond Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| US-11725001-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-08-15 | — | — | US | disclosed |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-06 | — | — | US | disclosed |
| EP-4157263-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | The Regents Of The University Of Michigan (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20220402902-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. | 2022-12-22 | — | — | US | disclosed |
| EP-3120852-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR IMMUNE DISEASES | Taiho Pharmaceutical Co., Ltd. (JP) | 2017-01-25 | — | — | EP | disclosed |
| EP-3115365-A1 | NOVEL SALT OF CONDENSED PYRIMIDINE COMPOUND, AND CRYSTALS THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2017-01-11 | — | — | EP | disclosed |
| US-20160324878-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2016-11-10 | — | — | US | disclosed |
| US-20140323464-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-30 | — | — | US | disclosed |
| EP-2710007-A2 | KINASE INHIBITORS | The Regents of the University of California (US) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012158843-A2 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | WO | disclosed |
| US-8119805-B2 | Substituted disulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100152158-A1 | Substituted Disulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-06-17 | — | — | US | disclosed |
| EP-1963304-A1 | ISOQUINOLINE DERIVATIVES | N.V. Organon (NL) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065916-A1 | ISOQUINOLINE DERIVATIVES | N.V. ORGANON (NL) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402902-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | TAAR1 4367/4885EPHX2 3328/4885GAA 3496/4885 |
| US-20100152158-A1 | Substituted Disulfonamide Compounds | BDKRB1, BDKRB2, BRS3 | TAAR1 51/4885EPHX2 3092/4885GAA 4666/4885 |
| US-20140323464-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | TAAR1 4245/4885EPHX2 3369/4885GAA 2400/4885 |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | TAAR1 4367/4885EPHX2 3328/4885GAA 3496/4885 |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT8 | TAAR1 4497/4885EPHX2 3518/4885GAA 3351/4885 |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | USP7, USP28, USP1 | TAAR1 4139/4885EPHX2 2191/4885GAA 192/4885 |
| US-20230047296-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | TAAR1 2709/4885EPHX2 996/4885GAA 2150/4885 |
| US-11725001-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | TAAR1 4367/4885EPHX2 3328/4885GAA 3496/4885 |
| US-20160324878-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | BTK, BCL9, BCL9L | TAAR1 4758/4885EPHX2 4189/4885GAA 1593/4885 |
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | TFAM, CS, FH | TAAR1 3807/4885EPHX2 3263/4885GAA 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.